Journal of the American College of Cardiology Vol. 48, No. 7, by the American College of Cardiology Foundation ISSN /06/$32.
|
|
- Mavis Lindsey
- 6 years ago
- Views:
Transcription
1 Journal of the American College of Cardiology Vol. 48, No. 7, by the American College of Cardiology Foundation ISSN /06/$32.00 Published by Elsevier Inc. doi: /j.jacc FOCUS ISSUE: CARDIAC INTERVENTION Benefit of a 600-mg Loading Dose of Clopidogrel on Platelet Reactivity and Clinical Outcomes in Patients With Non ST-Segment Elevation Acute Coronary Syndrome Undergoing Coronary Stenting Thomas Cuisset, MD,* Corinne Frere, MD, Jacques Quilici, MD,* Pierre-Emmanuel Morange, MD, PHD, Lyassine Nait-Saidi, MD,* Joseph Carvajal, MD, Agnès Lehmann, Marc Lambert, MD,* Jean-Louis Bonnet, MD,* Marie-Christine Alessi, MD, PHD Marseille, France OBJECTIVES BACKGROUND METHODS RESULTS CONCLUSIONS We analyzed the benefit of a 600-mg clopidogrel loading dose on platelet reactivity and clinical outcomes after stenting for non ST-segment elevation acute coronary syndrome (NSTE ACS). High post-treatment platelet reactivity (HPPR adenosine diphosphate 10 mol l 1 [ADP] induced platelet aggregation 70%) is a marker for low responders to dual antiplatelet therapy with increased risk of recurrent cardiovascular (CV) events after stenting for NSTE ACS. A total of 292 consecutive NSTE ACS patients undergoing coronary stenting were included and randomly received a 300-mg (n 146) or 600-mg (n 146) loading dose of clopidogrel at least 12 h before percutaneous coronary intervention. A single post-treatment blood sample was obtained before percutaneous coronary intervention to analyze maximal intensity of ADP-induced platelet aggregation and platelet surface expression of P-selectin. One-month follow-up CV events were recorded. The ADP-induced platelet aggregation and expression of P-selectin were significantly lower in patients receiving 600 mg than in those receiving 300 mg (mean SD: 50 19% vs %, p and arbitrary units vs arbitrary units; p respectively). Persistence of HPPR was less common in patients receiving 600 mg than in those receiving 300 mg (15 vs. 25%, p 0.03). During the 1-month follow-up, 18 CV events (12%) occurred in the 300-mg group versus 7 (5%) in the 600-mg group (p 0.02); this difference was not affected by adjustment for conventional CV risk factors (p 0.035). In NSTE ACS patients undergoing coronary stenting, a 600-mg loading dose of clopidogrel shows its benefit on platelet reactivity and clinical prognosis. (J Am Coll Cardiol 2006;48: ) 2006 by the American College of Cardiology Foundation Platelet reactivity plays a key role in the pathogenesis of ischemic complications after stenting for non ST-segment elevation acute coronary syndrome (NSTE ACS). Accordingly, platelet inhibition with a thienopyridine (clopidogrel) has significantly reduced recurrent ischemic events in this clinical setting, and in combination with aspirin, clopidogrel is now the treatment of choice for preventing stent thrombosis (1) and reducing major adverse cardiovascular (CV) events after NSTE ACS (2,3). Nevertheless, ischemic events still occur. These recurrences involve a complex and multifactorial process, and low response to antiplatelet therapy could be a major factor. Indeed numerous biological studies, essentially based on adenosine diphosphate (ADP)- induced platelet aggregometry, have reported interindividual variability in platelet response to clopidogrel (4 8); these studies identified patients who did not achieve platelet From the *Department of Cardiology, CHU Timone, Marseille, France; and INSERM, Faculté de Médecine CHU Timone, Marseille, France. This work was supported by the Assistance Publique Hôpitaux de Marseille. Manuscript received March 14, 2006; revised manuscript received May 30, 2006, accepted June 12, inhibition as low responders or resistants. However, antiplatelet effect monitoring would be of limited relevance in the absence of clinical implication. Precisely, as has been shown for aspirin (9), a relationship between clopidogrel resistance and recurrence of clinical outcomes has been reported in several studies (7,10 13). We previously showed that in NSTE ACS patients undergoing coronary stenting, the high post-treatment platelet reactivity (HPPR) (maximal intensity of ADP 10 mol l 1 induced platelet aggregation 70%) identified low responders to dual antiplatelet therapy (aspirin and clopidogrel) at higher risk of CV events during a 1-month follow-up (14). According to these results, other therapeutic approaches should be considered for these low-responder patients, such as higher doses or alternative treatments. Currently, the 300-mg loading dose of clopidogrel given at least 6 h before the procedure represents the conventional antiplatelet regimen before percutaneous coronary intervention (PCI). A higher loading dose of clopidogrel has already shown its capacity to improve platelet reactivity after treatment in healthy volun-
2 1340 Cuisset et al. JACC Vol. 48, No. 7, 2006 Platelet Reactivity and Acute Coronary Syndrome October 3, 2006: Abbreviations and Acronyms ADP adenosine diphosphate CREDO Clopidogrel for Reduction of Events During Observation CV cardiovascular HPPR high post-treatment platelet reactivity NSTE ACS non ST-segment elevation acute coronary syndrome PCI percutaneous coronary intervention PCI-CURE Percutaneous Coronary Intervention- Clopidogrel in Unstable Angina to Prevent Recurrent Events PRP platelet-rich plasma ST stent thrombosis teers and patients (15 21) with an earlier and stronger inhibition of ADP induced platelet activation than the 300-mg loading regimen, and its efficiency for the prevention of periprocedural infarction in stented patients (22). However, to the best of our knowledge, no study has ever tested both platelet parameters and clinical outcomes after increasing the loading dose of clopidogrel, especially in high-risk groups such as stented NSTE ACS patients. Therefore, we conducted a randomized and prospective study to evaluate the benefit of a higher loading dose of clopidogrel on platelet aggregation and recurrent ischemic events for NSTE ACS patients undergoing coronary stenting. METHODS Study population. Consecutive patients admitted for NSTE ACS to the Department of Cardiology of the Timone hospital between June 2004 and October 2005 were eligible for this prospective study if they had undergone successful coronary stenting. We defined NSTE ACS as clinical symptoms compatible with acute myocardial ischemia within 12 h before admission and at least 1 of the following: a new finding of ST-segment depression 0.05 mv, transient ( 20 min) ST-segment elevation 0.1 mv, T-wave inversion 0.3 mv in at least 2 leads, elevated levels of cardiac markers or coronary disease as documented by a history of catheterization, revascularization, or myocardial infarction. The exclusion criteria were a history of bleeding diathesis, persistent ST-segment elevation ACS, New York Heart Association functional class IV, PCI or coronary bypass grafting 3 months, contraindications to antiplatelet therapy, platelet count 100 g l 1, creatinine clearance 25 ml min 1, and use of glycoprotein IIb/IIIa inhibitors before the procedure. Patients were randomly assigned to receive a 300-mg or 600-mg loading dose of clopidogrel at least 12 h before stenting. All patients received aspirin 160 mg daily after a loading dose of 250 mg administered at least 12 h before stenting. The PCI was performed within 48 h after admission. For all patients, anticoagulation was begun before PCI in the intensive care unit and performed with low-molecular-weight heparin (enoxaparin), or unfractionated heparin in patients over 75 years old or with renal insufficiency. The study protocol was approved by the institutional ethics committee of our institution, and patients gave written informed consent for participation. Blood samples. Blood samples for testing platelet reactivity were drawn in the catheterization laboratory from a 6-F arterial sheath before the PCI at least 12 h after the loading dose of clopidogrel and aspirin, and before administration of tirofiban if needed. The initial first millimeters of blood were discarded to avoid platelet activation induced by needle puncture, and blood was immediately collected in Vacutainer tube containing 3.8% trisodium citrate, filled to capacity, and then inverted 3 to 5 times for gentle mixing and drawn immediately to the hemostasis laboratory. Platelet aggregation. The blood citrate mixture was centrifuged at 120 g for 5 min. The resulting platelet-rich plasma (PRP) was kept at room temperature for use within 1 h. The platelet count was determined in the PRP sample and adjusted to ml 1 with homologous plateletpoor plasma. Platelets were stimulated with ADP (10 mol l 1 ), and aggregation was assessed with a PAP4 Aggregometer (Biodata Corporation, Wellcome, Paris, France). Aggregation was expressed as the maximal percentage change in light transmittance from baseline with platelet-poor plasma as a reference. Here we report data on maximal intensity of platelet aggregation with ADP concentrations. The coefficient of variation of maximal intensity of platelet aggregation with ADP was 6.5%. Flow cytometry. The surface expression of the internal alpha-granule membrane protein P-selectin expressed on the surface of ADP activated platelets was determined by flow cytometry with monoclonal antibody. The following antibodies were used: anti-cd62p (Beckman Coulter, Fullerton, California) and antimouse goat immunoglobulin (Ig)G FITC (antimouse goat IgG labeled with fluorescein isothiocyanate; Beckman Coulter). Briefly, PRP was diluted 1:10 in tyrode albumin buffer ( ml 1 ) and gently mixed. Both antibody anti-cd62p (10 l of dilution 1:10) and ADP (final concentration 10 mol ml 1 ) or tyrode albumin buffer were added to 10 l of diluted PRP. After incubation in the dark at room temperature for 15 min, 10 l of antimouse goat IgG FITC (diluted 1:10) were added and again incubated in the dark at room temperature for 15 min. Scatter signals and fluorescence intensity were analyzed on a EPICS XL-MCL flow cytometer (Beckman Coultronics, Margency, France). The light-scattering properties projected on a scattergram identified the platelet cluster. Fluorescence intensity was expressed on individual cytohistograms, with the region of interest limited to the platelet cluster. The mean channel fluorescence intensity was used as an index of antibody binding and P-selectin surface expression. Platelet function end point. We analyzed the mean maximal intensity of ADP-induced platelet aggregation in both groups, receiving 300 mg or 600 mg of clopidogrel. We also reported the rate of persistence of HPPR, defined as
3 JACC Vol. 48, No. 7, 2006 October 3, 2006: Cuisset et al. Platelet Reactivity and Acute Coronary Syndrome 1341 ADP-induced platelet aggregation 70%, in both groups. Finally, we studied the expression of P-selectin to evaluate platelet activation. Clinical end point. The clinical end point included the following CV events: CV death, acute or subacute stent thrombosis, recurrent ACS, and stroke. Follow-up events were prospectively assessed by clinical visit. An ACS was defined by the presence of symptoms compatible with recurrent ischemia needing new hospitalization and coronary angiography, ischemic stroke was defined as a new focal neurologic deficit without bleeding on tomodensitometry and confirmed by a neurologist that as occurring within 1 month of PCI. Drug therapy compliance was assessed. Occurrence of major bleeding defined as intracranial bleeding or clinically overt bleeding associated with a decrease in hemoglobin of 5 g dl 1, according to the Thrombolysis in Myocardial Infarction criteria (23), were reported. The treating physician and the investigators who evaluated the clinical end points were blinded to the results of the platelet testing. Statistical analysis. Statistical analysis was performed with the SAS Software (version 9.01; SAS Institute Inc., Cary, North Carolina). Continuous variables are expressed as mean SD. Categorical variables are expressed as frequencies and percentages. For continuous variables, mean levels were compared between individuals with 300 mg and 600 mg of by analysis of variance, and for categorical variables, proportions were compared by chisquare test. Variables with a skewed distribution were log- or square root-transformed before analysis. The effect of the loading dose of clopidogrel on CV event was performed using logistic regression analysis. Three models were considered successively: Model 1: after adjustment for age and gender; Model 2: additionally adjusted for potential confounders such as conventional CV risk factors, treatment, and inflammatory parameters; Model 3: additionally adjusted for HPPR. RESULTS Patient characteristics. From June 2004 to October 2005, a total of 387 NSTE ACS patients who fulfilled the enrollment criteria were randomized to a 300-mg (n 192) or 600-mg (n 195) loading dose of clopidogrel. After coronary angiography, 95 patients who did not receive successful angioplasty were excluded from the study (72 were treated medically, 20 with elective bypass surgery and 3 with failed PCI). Of the 292 study patients with successful coronary stenting, 146 were randomized to a 300-mg and 146 to a 600-mg loading dose of clopidogrel. Demographic data of the studied population are summarized in Table 1. The demographic, clinical, and therapeutic parameters were similar in the 300-mg and 600-mg groups. The mean time between the loading dose of clopidogrel and blood sampling was h and h, respectively, for patients receiving 300 mg or 600 mg (p 0.56). All patients received 75 mg clopidogrel and 160 mg aspirin during the 1-month follow-up period. Platelet parameters. PLATELET AGGREGATION. We analyzed post-treatment platelet reactivity using the maximal intensity of ADP-induced platelet aggregation. The distribution of this response was consistent with a normal Table 1. Baseline Characteristics of the Patients According to the Loading Dose of Clopidogrel Characteristics 300 mg (n 146) 600 mg (n 146) p Value Age, yrs Men, n (%) 114 (79) 108 (73) 0.34 Hypertension, n (%) 84 (58) 81 (56) 0.67 Diabetes mellitus, n (%) 42 (29) 48 (33) 0.45 Current smoker, n (%) 59 (40) 76 (52) 0.06 Dyslipidemia, n (%) 81 (56) 79 (55) 0.81 Previous ACS, n (%) 65 (44) 66 (45) 0.90 Familial history, n (%) 49 (34) 53 (36) 0.62 Body mass index, kg/m Medications Statins, n (%) 87 (60) 88 (61) 0.90 Beta-blocker, n (%) 71 (49) 62 (42) 0.24 Diuretics, n (%) 24 (16) 24 (16) 1.00 Troponin, n (%) 38 (26) 30 (21) 0.27 ST-segment changes, n (%) 32 (22) 36 (25) 0.58 Left ventricular ejection fraction, % Creatinine, mol l Procedural features Total stent length, mm Tirofiban, n (%) 51 (35) 48 (33) 0.75 Anticoagulation LWMH 95 (65) 99 (68) 0.78 UFH 51 (35) 47 (32) 0.81 Values are mean SD for quantitative variables and n (%) for qualitative variables. For skewed variables, tests were performed on log-transformed values. ACS acute coronary syndrome; LMWH low molecular weight heparin; UFH unfractionated heparin.
4 1342 Cuisset et al. JACC Vol. 48, No. 7, 2006 Platelet Reactivity and Acute Coronary Syndrome October 3, 2006: Figure 1. Maximal intensity of adenosine diphosphate (ADP)-induced platelet aggregation in the 300-mg and 600-mg groups. bell-shaped distribution. Maximal intensity of ADPinduced platelet aggregation was significantly lower in patients who received a 600-mg loading dose of clopidogrel than in those who received 300 mg (mean SD: 50 19% vs %, p ) (Fig. 1). The persistence of HPPR was less common in patients receiving a 600-mg loading dose of clopidogrel (n 22, 15%) than in those receiving 300 mg (n 36, 25%, p 0.04). EXPRESSION OF P-SELECTIN. The mean expression of P-selectin was significantly lower in patients receiving a 600-mg loading dose of clopidogrel than in those receiving 300 mg ( arbitrary units vs arbitrary units; p ) (Fig. 2). Clinical outcomes. One-month follow up was completed in all patients. Twenty-five CV events (8.5%) occurred in the whole population during follow-up. Recurrent ischemic events occurred more frequently in the 300-mg group than in the 600-mg group: 18 (12%) and 7 (5%), respectively (p 0.02). This difference was not affected by adjustment for potential confounders such as age, gender, CV risk factors, troponin elevation, ST-segment changes, left ventricular ejection fraction, or tirofiban use (p 0.035). Distribution of the CV events was 15 hospitalizations for recurrent ACS (2 acute stent thrombosis), 2 strokes, and 1 CV death for the 300-mg group; and 6 hospitalizations for recurrent ACS (1 acute stent thrombosis) and 1 stroke for the 600-mg group (Figs. 3 and 4). Figure 3. Clinical outcomes according to loading dose of clopidogrel. ACS acute coronary syndrome; CV death cardiovascular death; CVE cardiovascular events; ST stent thrombosis. In both groups, HPPR contributed to recurrence of CV events after adjustment for age and gender: (OR [odds ratio] 9.93 [95% confidence interval (CI) 3.19 to 30.90] and OR [95% CI 4.89 to ], respectively, for 300-mg and 600-mg groups). In the 300-mg group, 67% (n 12) of clinical events occurred in patients with HPPR, and 85% (n 6) in the 600-mg group. When including both clopidogrel loading doses and persistence of HPPR as well as potential confounders in a logistic regression analysis, only persistence of HPPR remained independently associated with CV events (OR [95% CI 5.30 to ], p ). No patient in either group had postprocedural major bleeding or required transfusions. DISCUSSION Compared with the 300-mg clopidogrel loading dose, our study shows that a 600-mg bolus allows a superior antiplatelet effect and improves clinical outcomes in patients undergoing coronary stenting for NSTE ACS. Clopidogrel is an antiplatelet agent inhibiting the ADP receptor. Because of its safety profile and the results of clinical trials, clopidogrel has become the standard treatment for ACS and stenting (1 3). Two large studies in patients with ACS have shown that pretreatment with clopidogrel may have beneficial effects. This pretreatment was given a mean of 6 days before intervention in the observational PCI-CURE (Percutaneous Coronary Intervention Clopidogrel in Unstable An- Figure 2. Mean fluorescence intensity of P-selectin expression in the 300-mg and 600-mg groups. AU arbitrary units. Figure 4. Kaplan-Meier analysis for 30-day cardiovascular (CV) events according to loading dose of clopidogrel. Log-rank 9.24, p
5 JACC Vol. 48, No. 7, 2006 October 3, 2006: Cuisset et al. Platelet Reactivity and Acute Coronary Syndrome 1343 gina to Prevent Recurrent Events) (3) and 3 to 24 h in the randomized CREDO (Clopidogrel for the Reduction of Events During Observation) trial (24). Accordingly, current common clinical practice consists of pretreatment with a 300-mg loading dose of clopidogrel at least 6 h before the procedure in patients with ACS, as well as in those undergoing elective intervention. Despite the routine use of dual antiplatelet therapy with loading dose of clopidogrel, recurrent ischemic events occurred and antiplatelet responsiveness involvement emerged in numerous studies as a potential responsible factor. Clopidogrel resistance was initially supported by several biological studies usually based on ADP-induced platelet aggregation, which emphasized high interindividual variability of in vitro platelet response to standard dose of clopidogrel (4 8). Mechanisms involved are not yet clear; variability in intestinal absorption and the hepatic cytochrome P450 3A4 activity were reported as important factors (9). Moreover, several factors could modulate clopidogrel antiplatelet effectiveness. Indeed, a recent study by Saraff et al. (25) showed that the benefit of dual antiplatelet therapy with aspirin and clopidogrel was especially pronounced in smokers, probably because smoking increases platelet reactivity and smokers have poor outcomes after PCI compared with nonsmokers. In the present study, there was a trend toward an increased prevalence of smokers in the 600-mg group. It suggests that the benefit of a higher loading dose could have been greater without this difference between the 300-mg and 600-mg groups. The clinical relevance of the clopidogrel resistance has already been reported in several retrospective studies showing a correlation between platelet parameters and stent thrombosis (7,10 12). Only 2 prospective studies evaluated the relationship between clopidogrel responsiveness and recurrent ischemic events after ACS (13,14). Nevertheless, the lack of a standard definition of resistance as well as the lack of a standard diagnostic modality has hampered the field in identifying and treating this clinical entity. Consequently, some investigators suggested to study post-treatment platelet reactivity rather than antiplatelet responsiveness as a risk marker of clinical outcomes (14). Moreover, recent studies (14,26) proposed the ADPinduced post-treatment platelet aggregation as a means of evaluating the response both to clopidogrel and to aspirin. To determine a useful measurement of platelet reactivity in daily clinical practice, we use one single blood sample testing ADP-induced post-treatment platelet aggregation. We identified HPPR (ADP-induced platelet aggregation 70%), in spite of dual antiplatelet therapy with a 300-mg loading dose of clopidogrel as a risk marker of recurrent ischemic events (14). Therefore, the results of the present study confirmed that the HPPR have a predictive value for recurrent ischemic events in both the 300-mg and the 600-mg groups. Moreover, the multivariable analysis showed that the HPPR was a better predictor of clinical outcomes than the 300-mg or 600-mg loading dose, suggesting that the benefit of higher clopidogrel loading dose on clinical prognosis is directly linked to the decreasing persistence of HPPR. These supplementary data seem to validate the use of this marker in daily clinical practice to identify high-risk patients with persistent HPPR. The dose of 300 mg of clopidogrel derives from dosefinding data on healthy volunteers; however, patients with coronary artery disease may have enhanced platelet reactivity as compared with healthy individuals, and so probably require more aggressive platelet inhibition. Indeed, in an environment of high thrombin activity, it has been shown that clopidogrel might not reduce enough platelet activity because it did not inhibit the platelet aggregation and degranulation after stimulation with the thrombin-related activating peptide (27). Moreover, a study by Soffer et al. (28) has correlated the level of angina class with platelet inhibition by clopidogrel and found that patients with a higher Braunwald angina class had lower inhibition of platelet aggregation. The standard dose of 300 mg is probably not as efficient during ACS as it has been shown in healthy subjects. Plasma concentration of the active drug influences platelet aggregation after first administration in a dose-dependent manner (29). Thus, a more rapid and intense platelet suppression represents the rationale for pretreatment with a 600-mg loading dose of clopidogrel. Several studies have shown a benefit of higher clopidogrel loading on platelet aggregation with a decreased rate of nonresponders and platelet reactivity (15 21), and a previous study showed a benefit of 600 mg of clopidogrel compared with the standard 300-mg regimen on the incidence of periprocedural elevation of markers of myocardial necrosis (22). Even more recently, a dose of 900 mg was tested, although this did not seem to produce any more active metabolite or inhibition of platelet function than the 600-mg dose (20). In the present study, we showed both a biological and a clinical benefit of a higher loading dose of clopidogrel. Moreover, in our study, a higher loading dose of clopidogrel was not associated with important bleeding complications. Elsewhere, other antithrombotic strategies may be useful for these antiplatelet nonresponders at high risk of recurrent ischemic events. First, use in the periprocedural period of GPIIb/IIIa antagonist infusion would be beneficial in these patients. Indeed, a recent study has shown the lower clinical event rate after administration of abciximab in higher-risk NSTE ACS patients in spite of a 600-mg loading dose of clopidogrel (30). Secondly, the emergence of new ADP-antagonists such as prasugrel would probably be helpful in this clinical setting. Clinical studies are required to validate these hypotheses. Study limitations. It should be mentioned that the sample size of the present study is relatively small, and therefore does not allow for definitive conclusions. In our study, timing between the loading dose of clopidogrel and PCI was 12 to 24 h. However, a recent study by Steinhubl et al. (31) from the CREDO study showed that a 300-mg loading dose had no effect if administrated 15 h before PCI, and
6 1344 Cuisset et al. JACC Vol. 48, No. 7, 2006 Platelet Reactivity and Acute Coronary Syndrome October 3, 2006: that the effect was not optimal until approximately 24 h before PCI. Moreover, in the ISAR REACT (Intracoronary Stenting and Antithrombotic Regimen Rapid Early Action for Coronary Treatment) study with a 600-mg loading dose, no relationship was found between the duration of pretreatment (2 to 24 h) and clinical events (32). The design of our study could partially explain the benefit of a higher loading dose for patients pretreated with a 300-mg loading between 12 to 24 h before PCI. Finally, the clinical combined end point chosen in our study is obviously debatable, especially because the usually used periprocedural infarction, defined with elevation of creatine kinase-mb or troponin, was not included. Conclusions. Our study showed that pretreatment with a 600-mg loading dose of clopidogrel given before PCI for NSTE ACS is safe and, as compared with the 300-mg dose, improves periprocedural platelet inhibition and reduces recurrent ischemic events. The low risk and efficiency of this pharmacological regimen may support its routine use in ACS patients before PCI, as recently evoked in the European Society of Cardiology (33) and American College of Cardiology/American Heart association guidelines (34), but larger clinical studies are required. Reprint requests and correspondence: Dr. Marie-Christine Alessi, INSERM, UMR 626 Marseille, F France. Marie-Christine.Alessi@medecine.univ-mrs.fr. REFERENCES 1. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH, for the CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102: Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345: Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358: Gurbel PA, Bliden KP, Hiatt BL, O Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107: Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 2005;115: Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002;252: Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003;89: Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45: Wang TH, Bhatt DL, Topol E. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006;27: Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003;59: Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST study. J Am Coll Cardiol 2005;46: Wenaweser P, Hess O. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 2005;46: CS Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109: Cuisset T, Frere C, Quilici J, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006;4: Zidar FJ, Moliterno DJ, Bhatt DL, et al. High-dose clopidogrel loading rapidly reduces both platelet inflammatory marker expression and aggregation (abstr). J Am Coll Cardiol 2004;43 Suppl:64A. 16. Kastrati A, von Beckerath N, Joost A, Pogatsa-Murray G, Gorchakova O, Schomig A. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 2004;110: Gurbel PA, Bliden KP, Hayes KM, Young S, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005;45: Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 2005;111: Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 2004;25: von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005;112: Montalescot G. Assessment of the best loading dose of clopidogrel to blunt platelet activation, inflammation, and ongoing necrosis (ALBION) study. Paris, France: EuroPCR, Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, DiSciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention. Results From the ARMYDA-2 (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty) study. Circulation 2005;111: Rao AK, Pratt C, Berke A, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11: Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288: Saraff KY, Steinhubl SR, Hsu AP, Topol EJ, for the CREDO Investigators. Smoking influences the effectiveness of dual antiplatelet therapy on long-term outcomes following percutaneous coronary intervention (abstr). J Am Coll Cardiol 2006;47 Suppl B:36B. 26. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006;47: Muller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001;85: Soffer D, Moussa I, Harjai KJ, et al. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in
7 JACC Vol. 48, No. 7, 2006 October 3, 2006: Cuisset et al. Platelet Reactivity and Acute Coronary Syndrome 1345 patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? Catheter Cardiovasc Interv 2003;59: Caplain H, Donat F, Gaud C, Necciari J. Pharmacokinetics of clopidogrel. Semin Thromb Hemost 1999;25 Suppl 2: Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006;295: Steinhubl SR, Berger PB, Brennan DM, Topol EJ, CREDO Investigators. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 2006;47: Kandzari DE, Berger PB, Kastrati A, et al. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 2004;44: Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary intervention. The Task Force for Percutaneous Coronary Intervention of the European Society of Cardiology. Eur Heart J 2005;26: Smith SC Jr., Feldman TE, Hirshfeld JW Jr., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006;47:
Journal of the American College of Cardiology Vol. 45, No. 9, by the American College of Cardiology Foundation ISSN /05/$30.
Journal of the American College of Cardiology Vol. 45, No. 9, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.01.030
More informationComparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose
Journal of the American College of Cardiology Vol. 54, No. 13, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.05.050
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationJournal of the American College of Cardiology Vol. 50, No. 19, by the American College of Cardiology Foundation ISSN /07/$32.
Journal of the American College of Cardiology Vol. 50, No. 19, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.07.058
More informationClopidogrel 600-Mg Double Loading Dose Achieves Stronger Platelet Inhibition Than Conventional Regimens
Journal of the American College of Cardiology Vol. 51, No. 11, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.12.013
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationOral Antiplatelet Therapy in PCI/ACS. Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine
Oral Antiplatelet Therapy in PCI/ACS Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Basic Concepts Thrombus Formation Two key elements:
More informationContemporary issues on clopidogrel therapy
Intern Emerg Med (2009) 4:201 211 DOI 10.1007/s11739-008-0220-5 IM - REVIEW Contemporary issues on clopidogrel therapy Giuseppe Patti Æ Germano Di Sciascio Received: 23 July 2008 / Accepted: 4 December
More informationInterventional Cardiology
Interventional Cardiology Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets Results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS)
More informationOlga Gorchakova a, Nicolas von Beckerath b, *, Meinrad Gawaz a, Adrienne Mocz b, Alexander Joost b, Albert Schömig a,b, Adnan Kastrati b.
European Heart Journal (24) 25, 1898 192 Clinical research Antiplatelet effects of a mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks
More informationEffective platelet inhibition at the time of percutaneous
Time Dependence of Platelet Inhibition After a 600-mg Loading Dose of Clopidogrel in a Large, Unselected Cohort of Candidates for Percutaneous Coronary Intervention Willibald Hochholzer, MD; Dietmar Trenk,
More informationJournal of the American College of Cardiology Vol. 51, No. 14, by the American College of Cardiology Foundation ISSN /08/$34.
Journal of the American College of Cardiology Vol. 51, No. 14, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.12.044
More informationJournal of the American College of Cardiology Vol. 48, No. 11, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 48, No. 11, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.12.084
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationVariability in Platelet Responsiveness to Clopidogrel Among 544 Individuals
Journal of the American College of Cardiology Vol. 45, No. 2, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.09.067
More informationUse of Clopidogrel in the Reduction of Myocardial Damage During Percutaneous Coronary Intervention
University of Kentucky UKnowledge Gill Heart & Vascular Institute Faculty Publications Heart & Vascular 3-19-29 Use of Clopidogrel in the Reduction of Myocardial Damage During Percutaneous Coronary Intervention
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationClopidogrel has been evaluated in clinical trials that included cardiovascular patients
REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,
More informationPlatelet resistance is best defined as a lack of the desired pharmacologic effect
2Chapter 1 Anti-Platelet Resistance Oral Antiplatelet Therapy Resistance: Definition, diagnosis, and clinical implications Saurabh Gupta, MD Peter J. Casterella, MD Executive Summary Platelet resistance
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationP2Y 12 blockade. To load or not to load before the cath lab?
UPDATE ON ANTITHROMBOTICS IN ACUTE CORONARY SYNDROMES P2Y 12 blockade. To load or not to load before the cath lab? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria,
More informationIncreased Risk in Patients With High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary Intervention
Journal of the American College of Cardiology Vol. 49, No. 6, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.10.050
More informationRandomized Comparison of Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With High Post-Treatment Platelet Reactivity
Journal of the American College of Cardiology Vol. 53, No. 13, 9 9 by the American College of Cardiology Foundation ISSN 735-97/9/$36. Published by Elsevier Inc. doi:.16/j.jacc.8.12.25 CLINICAL RESEARCH
More informationA Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in Patients with Non-ST Elevation ACS
Angioplasty to Blunt the rise Of troponin in Acute coronary syndromes Randomized for an immediate or Delayed intervention A Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in
More informationNew Study Shows Prasugrel Achieves Faster Onset and Higher Levels of Platelet Inhibition than Clopidogrel at Approved or Higher Doses
October 23, 2006 Refer to: Joedy Isert Eli Lilly and Company 317-276-5592 (office) 317-997-8544 (cell) Jo-ann Straat Daiichi Sankyo (USA) 973-359-2602 (office) Shigemichi Kondo Daiichi Sankyo (Tokyo) 81-3-6225-1126
More informationNew insights in stent thrombosis: Platelet function monitoring. Franz-Josef Neumann Herz-Zentrum Bad Krozingen
New insights in stent thrombosis: Platelet function monitoring Franz-Josef Neumann Herz-Zentrum Bad Krozingen New insights in stent thrombosis: Platelet function monitoring Variability of residual platelet
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Optimising Crossover from Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome [CAPITAL OPTI-CROSS] Monique Conway, PharmD, BCPS PGY-2 Cardiology Pharmacy
More informationEvaluation of Clopidogrel Resistance. in ischemic stroke patients.
ORIGINAL ARTICLE Evaluation of Clopidogrel Resistance in Ischemic Stroke Patients Takuya Fukuoka, Daisuke Furuya, Hidetaka Takeda, Tomohisa Dembo, Harumitu Nagoya, Yuji Kato, Ichiro Deguchi, Hajime Maruyama,
More informationAbciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI. ISAR-REACT 4 Trial
Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI ISAR-REACT 4 Trial Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität, Munich, Germany On behalf of F.-J.
More informationPoint-of-Care Assessment of Platelet Reactivity After Clopidogrel to Predict Myonecrosis in Patients Undergoing Percutaneous Coronary Intervention
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 3, NO. 3, 2010 2010 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/10/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2009.12.012 Point-of-Care
More informationNOVEL ANTI-THROMBOTIC THERAPIES FOR ACUTE CORONARY SYNDROME: DIRECT THROMBIN INHIBITORS
Judd E. Hollander, MD Professor, Clinical Research Director, Department of Emergency Medicine University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania OBJECTIVES: 1. Discuss the concept
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationAntiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy
Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy Franz-Josef Neumann Herz-Zentrum Bad Krozingen Antiplatelet and Antithrombotic Therapies in PCI Defining the Optimal Strategy
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationAntiplatelet agents treatment
Session III Comprehensive management of diabetic patients Antiplatelet agents treatment Chonnam National University Hospital Department of Internal Medicine Dong-Hyeok Cho CONTENTS Introduction Prothrombotic
More informationHeart disease is the leading cause of death
ACS AND ANTIPLATELET MANAGEMENT: UPDATED GUIDELINES AND CURRENT TRIALS Christopher P. Cannon, MD,* ABSTRACT Acute coronary syndrome (ACS) is an important cause of morbidity and mortality in the US population
More informationVariability in Individual Responsiveness to Clopidogrel
Journal of the American College of Cardiology Vol. 49, No. 14, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.11.044
More informationThe ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) Study
Journal of the American College of Cardiology Vol. 52, No. 23, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.08.047
More informationThe Antiplatelet Effect of Higher Loading and Maintenance Dose Regimens of Clopidogrel
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 1, NO. 6, 2008 2008 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/08/$34.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2008.09.005 MINI-FOCUS:
More informationA Randomized Comparison of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin After the Placement of Coronary Artery Stents
Journal of the American College of Cardiology Vol. 41, No. 6, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02974-1
More informationAn update on the management of UA / NSTEMI. Michael H. Crawford, MD
An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB
More informationL Bonello, L Camoin-Jau, S Arques, C Boyer, D Panagides, O Wittenberg, MC Siméoni, P Barragan, F Dignat-George, F Paganelli.
Adjusted Clopidogrel Loading Doses According to VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel low response: A Multicentre Randomized Prospective
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial
ARMYDA-RECAPTURE ( for Reduction of MYocardial Damage during Angioplasty) trial Prospective, multicenter, randomized, double blind trial investigating efficacy of atorvastatin reload in patients on chronic
More informationPatient characteristics Intervention Comparison Length of follow-up
ANTIPLATELET CHAPTER Aspirin compared with placebo Ref ID: 4158 Reference Antithrombotic TC. Collaborative meta-analysis randomised trials antiplatelet therapy for prevention death, myocardial infarction,
More informationAnti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib!
Anti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib! Roxana Mehran, MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Research support
More informationOtamixaban for non-st-segment elevation acute coronary syndrome
Otamixaban for non-st-segment elevation acute coronary syndrome September 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationC.R.E.D.O. Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind Placebo Controlled Trial
Clopidogrel for the Reduction of Events During Observation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind Placebo Controlled Trial From Steinhubl et al, JAMA 2002;228:2411-20
More informationStudy objectives. Study design. Patient population
Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the GRAVITAS trial Matthew J. Price, MD,
More informationCOMPARISON OF LOADING DOSE OF 300mg VERSUS 600mg OF CLOPIDOGREL ON PLATELET AGGREGTION IN PATIENTS WITH CORONARY ARTERY DISEASE
VOL. 39 NO. 3 4 JULY - DECEMBER 2006 PAKISTAN HEART JOURNAL COMPARISON OF LOADING DOSE OF 300mg VERSUS 600mg OF CLOPIDOGREL ON PLATELET AGGREGTION IN PATIENTS WITH CORONARY ARTERY DISEASE SUMMARY MOHAMMAD
More informationUpdate on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More informationContinuing Medical Education Post-Test
Continuing Medical Education Post-Test Based on the information presented in this monograph, please choose one correct response for each of the following questions or statements. Record your answers on
More information(ClinicalTrials.gov ID: NCT ) Title: The Italian Elderly ACS Study Author: Stefano Savonitto. Date: 29 August 2011 Meeting: ESC congress, Paris
Early aggressive versus initially conservative strategy in elderly patients with non-st- elevation acute coronary syndrome: the Italian randomised trial (ClinicalTrials.gov ID: NCT00510185) Stefano Savonitto,
More informationNovel Anticoagulation Therapy in Acute Coronary Syndrome
Novel Anticoagulation Therapy in Acute Coronary Syndrome Soon Jun Hong Korea University Anam Hospital 1 Thrombus Formation Cascade Coagulation Cascade Platelet Cascade TXA2 Aspirin R Inhibitor Fondaparinux
More informationDo We Need Platelet Function Assays?
Do We Need Platelet Function Assays? Matthew J. Price MD Director, Cardiac Catheterization Laboratory Scripps Clinic, La Jolla, CA The Antiplatelet Effect of Clopidogrel Varies Widely Among Individuals
More informationApproval for publication Signed Date Number of amended pages returned
Approval for publication Signed Date Number of amended pages returned ORIGINAL RESEARCH ARTICLE Am J Cardiovasc Drugs 2009; 9 (6): 1-7 1175-3277/09/0006-0001/$49.95/0 ª 2009 Adis Data Information BV. All
More informationKeywords Non ST-segment elevation ACS Antithrombotic therapy Glycoprotein IIb/IIIa inhibitor Tirofiban. Introduction
J Thromb Thrombolysis (2007) 24:241 246 DOI 10.1007/s19-007-0015-y Routine upstream versus selective down stream use of tirofiban in non-st elevation myocardial infarction patients scheduled for early
More informationRandomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction
Randomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction The Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4
More informationInter-regional differences and outcome in unstable angina
European Heart Journal (2000) 21, 1433 1439 doi:10.1053/euhj.1999.1983, available online at http://www.idealibrary.com on Inter-regional differences and outcome in unstable angina Analysis of the International
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 9, 2013 Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville
More informationDirect Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI
Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI Charles A. Simonton MD, FACC, FSCAI Sanger Clinic Medical Director Clinical Innovation and Research Carolinas Heart
More informationUpcoming Evidence and Practice of Optimal Antiplatelet Therapy in DES Era?
Upcoming Evidence and Practice of ptimal Antiplatelet Therapy in DES Era? Polymorphism in Metabolism of Clopidogrel and Its Clinical Implications and Management Alexandra Lansky MD Columbia University
More informationEarly and Late Benefits of Prasugrel in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
Journal of the American College of Cardiology Vol. 51, No. 21, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.04.002
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationSlow Response to Clopidogrel Predicts Low Response
Journal of the American College of Cardiology Vol. 55, No. 8, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/10/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.08.082
More informationFacilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. Is it beneficial to patients?
Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction Is it beneficial to patients? Seung-Jea Tahk, MD. PhD. Suwon, Korea Facilitated PCI.. background Degree of coronary flow at
More informationReview Article Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes
Review Article Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes Tirtha Patel V *, Jigna Shah S and Patel CN Department of Clinical Pharmacy, Shri Sarvajanik Pharmacy College, Mehsana, Gujarat,
More information2007 ACC/AHA GUIDELINES FOR THE MANAGEMENT OF NSTE-ACS: OPTIMAL ANTICOAGULATION AND ANTIPLATELET THERAPY
2007 ACC/AHA GUIDELINES FOR THE MANAGEMENT OF NSTE-ACS: OPTIMAL ANTICOAGULATION AND ANTIPLATELET THERAPY Charles V. Pollack, Jr., MA, MD, FACEP, FAAEM, FAHA Professor and Chairman, Department of Emergency
More informationTreatment Strategies for the Prevention of Ischemic Complications in Patients Undergoing Percutaneous Coronary Intervention with Stent Placement
Treatment Strategies for the Prevention of Ischemic Complications in Patients Undergoing Percutaneous Coronary Intervention with Stent Placement Pharmaceutical Care Project Outcomes Literature Evaluation
More informationST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department
ST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department decision-making. They have become the cornerstone of many ED protocols for
More informationLow-dose aspirin increases aspirin resistance in patients with coronary artery disease
The American Journal of Medicine (2005) 118, 723-727 CLINICAL RESEARCH STUDY AJM Theme Issue: CARDIOLOGY Low-dose aspirin increases aspirin resistance in patients with coronary artery disease Pui-Yin Lee,
More informationPlatelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary
Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary Dániel Aradi MD PhD Interventional Cardiologist Assistant professor
More informationSurveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
More informationΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ. Εξατοµικευµένη αντιαιµοπεταλιακή αγωγή. Ποιο είναι το µέλλον?
ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ ΕΡΕΥΝΗΤΙΚΟ ΚΕΝΤΡΟ ΑΘΗΡΟΘΡΟΜΒΩΣΗΣ Εξατοµικευµένη αντιαιµοπεταλιακή αγωγή. Ποιο είναι το µέλλον? Αλέξανδρος Δ. Τσελέπης, MD, PhD Καθηγητής Βιοχηµείας - Κλινικής Χηµείας Disclosures
More informationInterventional Cardiology
Clinical Investigations Interventional Cardiology Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: Insights from the very early outcomes in the
More informationPrasugrel a step ahead in antiplatelet therapy
Prasugrel a step ahead in antiplatelet therapy VS Srinath, MD (Med), DNB (Cardiology) The burden of atherosclerotic disease in the United States and across the world is vast. Although the symptoms of atherosclerosis
More informationAntiplatelet and anticoagulant therapy for non-st-elevation acute coronary syndromes in a general hospital
Antiplatelet and anticoagulant therapy for non-st-elevation acute coronary syndromes in a general hospital Authors G. Mason*, F. Wirth**, A. Cignarella***, R.G. Xuereb****, L.M. Azzopardi***** *Final Year
More informationAbstract Background: Methods: Results: Conclusions:
Two-Year Clinical and Angiographic Outcomes of Overlapping Sirolimusversus Paclitaxel- Eluting Stents in the Treatment of Diffuse Long Coronary Lesions Kang-Yin Chen 1,2, Seung-Woon Rha 1, Yong-Jian Li
More informationHigh-Dose Tirofiban Administered as Bolus-Only during Percutaneous Coronary Intervention
Original Contribution High-Dose Tirofiban Administered as Bolus-Only during Percutaneous Coronary Intervention Jonathan D. Marmur, MD, Shyam Poludasu, MD, Ajay Agarwal, MD, Nagarathna Manjappa MD, Erdal
More informationAPPLICATION OF GENETIC TESTING FOR CYP 450 POLYMORPHISM TO PREDICT RESPONSE TO CLOPIDOGREL INPATIENT UNDERGOING PCI
INDIAN JOURNAL OF CARDIOVASCULAR DISEASES JOURNAL in women (IJCD) 2017 VOL 2 ISSUE 2 ORIGINAL ARTICLE 1 APPLICATION OF GENETIC TESTING FOR CYP 450 POLYMORPHISM TO PREDICT RESPONSE TO CLOPIDOGREL INPATIENT
More informationPrise en charge du SCA en amont de la salle de KT: aspirine seule ou dose de charge d un inhibiteur de la P2Y12?
Prise en charge du SCA en amont de la salle de KT: aspirine seule ou dose de charge d un inhibiteur de la P2Y12? La Baule Le 17 Mai 2014 Philippe Castellant CHU de Brest, Département de Cardiologie UBO,
More informationLinköping University Post Print. Atrial fibrillation and platelet reactivity
Linköping University Post Print Atrial fibrillation and platelet reactivity Micha Milovanovic, Elisabeth Fransson, Claes Hallert and Petter Järemo N.B.: When citing this work, cite the original article.
More informationAppendix: ACC/AHA and ESC practice guidelines
Appendix: ACC/AHA and ESC practice guidelines Definitions for guideline recommendations and level of evidence Recommendation Class I Class IIa Class IIb Class III Level of evidence Level A Level B Level
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationGuideline for STEMI. Reperfusion at a PCI-Capable Hospital
MANSOURA. 2015 Guideline for STEMI Reperfusion at a PCI-Capable Hospital Mahmoud Yossof MANSOURA 2015 Reperfusion Therapy for Patients with STEMI *Patients with cardiogenic shock or severe heart failure
More informationConference Paper Antithrombotic Therapy in Patients with Acute Coronary Syndromes: Biological Markers and Personalized Medicine
Conference Papers in Medicine, Article ID 719, pages http://dx.doi.org/1.1155/13/719 Conference Paper Antithrombotic Therapy in Patients with Acute Coronary Syndromes: Biological Markers and Personalized
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationOral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationIndex. Note: Page numbers of article titles are in boldface type.
Cardiol Clin 24 (2006) 299 304 Index Note: Page numbers of article titles are in boldface type. A Abciximab in PCI, 180 182 ACE trial, 182 Actinomycin D-eluting stent, 224 ACUITY trial, 190 Acute myocardial
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 8, 2014
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 8, 2014 Theodore A Bass, MD FSCAI Immediate Past-President SCAI Professor of Medicine, University of Florida Medical Director UF Health CV
More informationISAR-CHOICE 2. Randomized Trial of 75 mg vs 150 mg of Daily Clopidogrel in Patients Undergoing PCI
ISAR-CHOICE 2 Randomized Trial of 75 mg vs 150 mg of Daily Clopidogrel in Patients Undergoing PCI Adnan Kastrati Deutsches Herzzentrum, Munich, GERMANY Variability in Platelet Response to Clopidogrel Serebruany
More informationThe Evolving Role of Glycoprotein IIb/IIIa Inhibitors in the Setting of Percutaneous Coronary Intervention
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 3, NO. 12, 2010 2010 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2010.09.015 STATE-OF-THE-ART
More informationDownloaded from:
Annemans, L; Danchin, N; Van de Werf, F; Pocock, S; Licour, M; Medina, J; Bueno, H (2016) Prehospital and in-hospital use of healthcare resources in patients surviving acute coronary syndromes: an analysis
More informationIs Cangrelor hype or hope in STEMI primary PCI?
Is Cangrelor hype or hope in STEMI primary PCI? ARUN KALYANASUNDARAM MD, MPH, FSCAI HOPE Issues with platelet inhibition in STEMI Delayed onset In acute settings, achieving the expected antiplatelet effect
More informationBenefit of Early Invasive Therapy in Acute Coronary Syndromes A Meta-Analysis of Contemporary Randomized Clinical Trials
Journal of the American College of Cardiology Vol. 48, No. 7, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.06.050
More informationClopidogrel resistance?
Thrombosis Research (2007) 120, 311 321 intl.elsevierhealth.com/journals/thre REVIEW ARTICLE Clopidogrel resistance? Paul A. Gurbel, Udaya S. Tantry Sinai Center for Thrombosis Research, Baltimore, Maryland,
More information